CLS reported FY 2025 net sales of SEK 17.5 million (-7%), with the decline attributed to reduced net sales outside neurosurgery and alignment discussions on scaling in neurosurgery. Gross margin improved to 67% (from 51% in FY 2024), and operating expenses fell 38% versus FY 2024. The company said operating profit improved by SEK 25.4 million versus FY 2024. CLS strengthened its financial base through a SEK 35 million capital raise in 2025 and said it remains debt-free with no interest expenses. In neurosurgery, CLS said sales of Prism products rose 14% year-over-year, supported by its strategic partner’s market share gains and a doubling of Prism procedures in the U.S. Q4 Prism sales were negatively impacted by alignment discussions with the neurosurgery partner on scaling. During the year, CLS expanded FDA clearance for the ClearPoint Prism Neuro Laser Therapy System to include both 1.5T and 3.0T MRI guidance, and completed the first 1.5T Prism system installations in the U.S.; it also submitted a CE-mark application in Europe for 1.5T and 3.0T use. After the period, CLS reported installation of the TRANBERG Thermal Therapy System at Andros Clinics in Amsterdam via distributor MTEC for ultrasound-guided focal laser ablation in localized prostate cancer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CLS - Clinical Laserthermia Systems AB published the original content used to generate this news brief via Cision (Ref. ID: 20260220:BIT:4168:0) on February 20, 2026, and is solely responsible for the information contained therein.